Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials-Reference-Cited by-同舟云学术

Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials

Published:2019-04-08 Issue:1 Volume:18 Page:
ISSN:1475-2840
Container-title:Cardiovascular Diabetology
language:en
Short-container-title:Cardiovasc Diabetol

Author:

Yang Da-ya,He Xin,Liang Hui-wei,Zhang Shao-zhao,Zhong Xiang-bin,Luo Chu-fan,Du Zhi-min,He Jian-gui,Zhuang Xiao-dong,Liao Xin-xue

Funder

Medical Science and Technology Foundation of Guangdong Province

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1186/s12933-019-0853-x.pdf

Reference69 articles.

1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34.

2. Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation. 2004;110(12):1572–8.

3. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377–85.

4. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669–77.

5. Solomon SD, St John Sutton M, Lamas GA, Plappert T, Rouleau JL, Skali H, et al. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation. 2002;106(10):1251–5.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis;2023-02-01

2. Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis;Journal of General Internal Medicine;2021-11-30

3. Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials;Pharmacological Research;2021-09

4. Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients;Transplantation;2021-06-23

5. Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin;PharmacoEconomics;2020-11-05